Finance

Beta
Lists
PLUR:TLV
Pluri Inc
ILA 670.10
-0.45%
(-3.00) 1D
Jun 4, 11:47:52 AM GMT+3  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for PLUR...
Open
ILA 665.00
High
ILA 670.10
Low
ILA 665.00
Mkt. cap
25.30M
Avg. vol.
4.87K
Volume
794.00
52-wk high
ILA 1,920.00
52-wk low
ILA 665.00
Shares outstanding
10.79M
No. of employees
135
Open
ILA 665.00
High
ILA 670.10
Low
ILA 665.00
Mkt. cap
25.30M
Avg. vol.
4.87K
Volume
794.00
52-wk high
ILA 1,920.00
52-wk low
ILA 665.00
Shares outstanding
10.79M
No. of employees
135
News stories
From sources across the web
Profile
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas. Wikipedia
About Pluri Inc
CEOYaky Yanay
Employees135
FoundedMay 11, 2001
HeadquartersHaifa, Haifa District, Israel
SectorBiotechnology
Websitepluri-biotech.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
398.00K
316.00K
198.00K
167.00K
Cost of goods sold
191.00K
201.00K
112.00K
111.00K
Cost of revenue
191.00K
201.00K
112.00K
111.00K
Research and development expenses
3.99M
3.93M
3.83M
3.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.83M
2.53M
2.77M
2.63M
Operating expense
6.83M
6.46M
6.59M
6.59M
Total operating expenses
7.02M
6.67M
6.70M
6.70M
Operating income
-6.62M
-6.35M
-6.51M
-6.54M
Other non operating income
742.00K
289.00K
53.00K
6.00K
EBT including unusual items
-7.77M
-6.14M
-6.88M
-6.18M
EBT excluding unusual items
-7.77M
-6.14M
-6.88M
-6.18M
Income tax expense
-5.00K
-8.00K
-8.00K
-8.00K
Effective tax rate
0.06%
0.13%
0.12%
0.13%
Other operating expenses
-
-
-
-
Net income
-7.60M
-5.85M
-6.54M
-5.55M
Net profit margin
-1,909.05%
-1,851.27%
-3,304.55%
-3,322.16%
Earnings per share
-1.00
-0.65
-
-
Interest and investment income
312.00K
193.00K
118.00K
104.00K
Interest expense
-233.00K
-229.00K
-231.00K
-237.00K
Net interest expenses
79.00K
-36.00K
-113.00K
-133.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.51M
-6.22M
-6.38M
-6.41M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer